ReviewTranslational oncology2020
Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review.
Review in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Pooled it
- Value of radiomics model based on enhanced computed tomography in risk grade prediction of gastrointestinal stromal tumors.Scientific reports · 2021Trial
- Predicting the prognosis of small intestinal stromal tumors in the post-imatinib era: a study based on the SEER database.Translational cancer research · 2026Article
- Role of cytoreductive surgery in the management of peritoneal metastases for gastrointestinal stromal tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Giant jejunal gastrointestinal stromal tumour (GIST) in a young female: a fatal case of diagnostic delay revealed at autopsy.Forensic science, medicine, and pathology · 2026Article
- Ruptured Uterine Leiomyosarcoma With Heterologous Components Including Osteosarcoma and Chondrosarcoma.Journal of medical cases · 2026Article
- Genetic Variations in the M6A Modification Pathway as Potential Predictors of Imatinib Secondary Resistance in Gastrointestinal Stromal Tumors.Journal of clinical medicine · 2026Article
- Retrospective comparison of precutting endoscopic band ligation and endoscopic submucosal dissection for small gastric muscularis propria tumors.World journal of gastrointestinal endoscopy · 2026Article
- Gene, genetics and genetic medicines in gastroenterology: Current status and its future.World journal of gastroenterology · 2026Review
- Small bowel obstruction from jejunal gastrointestinal stromal tumour in a young adult with neurofibromatosis type 10: a case report.Journal of surgical case reports · 2026Article
- Study on risk stratification and treatment strategy of blood indicators in patients with moderate risk of GIST.Frontiers in oncology · 2026Article
- Article
- Clinicopathological characteristics and long-term prognosis of peritoneal and retroperitoneal gastrointestinal stromal tumors.Surgical endoscopy · 2025Article
- Characteristics and therapeutic strategies for familial gastrointestinal stromal tumors.World journal of gastrointestinal oncology · 2025Article
- Trends and Financial Burden of Gastrointestinal Stromal Tumors in the United States: A Comprehensive Analysis of United States Hospitalizations.Gastroenterology research · 2025Article
- Age-dependent diminution of female prognostic advantage in gastrointestinal stromal tumors: a retrospective cohort analysis.Frontiers in immunology · 2025Article
- Survival trends of gastrointestinal stromal tumor in real-world settings: a population-based retrospective study.Pathology oncology research : POR · 2025Article
- Exploring nanotechnology solutions for improved outcomes in gastrointestinal stromal tumors.Heliyon · 2024Review
- Primary gastrointestinal stromal tumor of the liver: a case report.Annals of medicine and surgery (2012) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are potentially malignancies that can occur anywhere in the digestive tract. Tyrosine kinase inhibitors (TKIs) such as imatinib have proven effective since the discovery of KIT and PDGFRA. The current version of NCNN, ESMO and EURACAN guidelines recognized that the three main prognostic factors are the mitotic rate, tumor size and tumor site. In addition, tumor rupture is also recognized as an independent risk factor. However, recent evidence shows that various types of gene mutations are associated with prognosis, and influencing factors such as gastrointestinal bleeding and high Ki67 index have been associated with poor prognosis. It shows that the current risk classification is still insufficient and controversial. With the emergence of more and more lack mutation in KIT/PDGFRA GISTs (KIT/PDGFRA wild-type GISTs) or drug resistance genes, primary and secondary drug resistance problems are caused, which makes the treatment of late or metastatic GIST face challenges. Therefore, this article will review the clinicopathological characteristics of GIST, the special molecular subtypes and other factors that may affect prognosis. We will also explore reliable prognostic markers for better postoperative management and improve the prognosis of patients with GIST.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.